Dr. Henry Lowe is the Co-Founder and Executive Chairman of Flavocure Biotech, Inc., and the co-inventor of the company’s foundational intellectual property portfolio. A globally recognized authority in drug discovery and development, Dr. Lowe has dedicated his career to unlocking the therapeutic potential of plant-derived compounds, pioneering research at the intersection of natural products science and modern medicine to address some of the world’s most challenging chronic diseases, including cancer, neurodegenerative diseases, and diabetes.
Dr. Lowe holds a PhD in Medicinal Chemistry from the University of Manchester, United Kingdom, and brings an extraordinary breadth of scientific and executive leadership to Flavocure. His distinguished career spans academia, industry, and public health including his tenure as Chairman and Chief Executive Officer of Blue Cross Blue Shield of Jamaica, where he demonstrated the same visionary leadership, he now applies to transforming the biotechnology landscape. He currently serves as an Adjunct Professor at the University of Maryland School of Medicine, where he continues to contribute to the training of the next generation of biomedical scientists. Dr. Lowe is the recipient of numerous awards, including a Proclamation from the United States House of Representatives, honoring his contributions to science, science education, and exemplary public service, 2013.
A prolific scholar and inventor, Dr. Lowe is the co-author of numerous peer-reviewed scientific publications and holds 9 patents on his scientific innovations, discoveries that form the cornerstone of Flavocure’s therapeutic pipeline and intellectual property strategy. His lifelong conviction that nature holds the key to medicine’s most important breakthroughs continues to drive Flavocure’s mission to deliver transformative, plant-derived therapies to patients who need them most.
Dr. Ngeh J. Toyang is the Co-Founder and Chief Executive Officer of Flavocure Biotech, Inc., a clinical-stage biotechnology company pioneering precision therapeutics at the intersection of oncology and neurology. With over 15 years of distinguished research experience in natural products science and pharmacognosy, Dr. Toyang has built his career at some of the world’s leading research institutions including the National Center for Natural Products Research at the University of Mississippi School of Pharmacy, the Natural Products Research Laboratory at Leiden University in The Netherlands, and the Institute of Human Virology at the University of Maryland School of Medicine.
Dr. Toyang earned his PhD specializing in Pharmacognosy from Leiden University, where he developed a deep expertise in the discovery and translational development of bioactive natural compounds. This scientific foundation has guided his work at Flavocure, where he leads a program focused on converting nature-derived molecules into next-generation therapeutics for cancer and neurodegenerative disease.
A prolific inventor and scientist, Dr. Toyang is the co-author of numerous peer-reviewed publications and holds seven patents protecting the proprietary compounds and platforms he has developed, including the foundational intellectual property covering Caflanone (FBL-03G), Flavocure’s lead oncology and CNS candidate. His leadership has been instrumental in advancing Flavocure’s pipeline to the clinical stage, securing two FDA Orphan Drug Designations and FDA clearance of an Investigational New Drug Application for a Phase I clinical trial in pancreatic cancer, a milestone that positions Flavocure at the forefront of a new era in immunomodulation-directed cancer therapy.
Dr. David Brooks has over 15 years of experience in drug development leading clinical and translational research. Dr. Brooks has overseen and/or led the 2 drugs that have been approved by the US FDA. He has extensive experience preparing all the clinical and biomarker sections for 9 IND applications over the last 16 years. All of these clinical research projects have involved extremely close communication, coordination and collaboration with leading academic institutions throughout the USA and the biotechnology companies. He has specific experience planning and overseeing pancreatic adenocarcinoma clinical trials which led to the (very rare) successful approval of Abraxane for this tumor type. Dr. Brooks holds MD and PhD degrees from Cornell University.
Thomas Lang is an experienced pharmaceutical and biotech industry veteran, graduating with degrees in Chemistry and Pharmacy. Dr. Lang previously served as the President and Vice Chairman of Serono, Inc., a biopharmaceutical business headquartered in Geneva, Switzerland. He has participated in the successful development and commercialization of 12 products in the areas of HIV/AIDS, Infertility and Reproductive Health, Growth, Metabolism and Endocrinology, CNS, Surgical Muscle Relaxants, Allergy Immunotherapy, and Multiple Sclerosis. At Flavocure he oversees the implementation of all IND-enabling studies and preparation of the IND filing package with the FDA.
Douglas graduated magna cum laude from The Ohio State University with a bachelor’ s degree in Finance and International Business. He has served in various corporate finance/accounting capacities in several publicly-traded biotech companies for over 20 years and was instrumental in SEC reporting and multiple rounds of public and private financing in those companies.
Dr. Henry Lowe is the Co-Founder and Executive Chairman of Flavocure Biotech, Inc., and the co-inventor of the company’s foundational intellectual property portfolio. A globally recognized authority in drug discovery and development, Dr. Lowe has dedicated his career to unlocking the therapeutic potential of plant-derived compounds, pioneering research at the intersection of natural products science and modern medicine to address some of the world’s most challenging chronic diseases, including cancer, neurodegenerative diseases, and diabetes.
Dr. Lowe holds a PhD in Medicinal Chemistry from the University of Manchester, United Kingdom, and brings an extraordinary breadth of scientific and executive leadership to Flavocure. His distinguished career spans academia, industry, and public health including his tenure as Chairman and Chief Executive Officer of Blue Cross Blue Shield of Jamaica, where he demonstrated the same visionary leadership, he now applies to transforming the biotechnology landscape. He currently serves as an Adjunct Professor at the University of Maryland School of Medicine, where he continues to contribute to the training of the next generation of biomedical scientists. Dr. Lowe is the recipient of numerous awards, including a Proclamation from the United States House of Representatives, honoring his contributions to science, science education, and exemplary public service, 2013.
A prolific scholar and inventor, Dr. Lowe is the co-author of numerous peer-reviewed scientific publications and holds 9 patents on his scientific innovations, discoveries that form the cornerstone of Flavocure’s therapeutic pipeline and intellectual property strategy. His lifelong conviction that nature holds the key to medicine’s most important breakthroughs continues to drive Flavocure’s mission to deliver transformative, plant-derived therapies to patients who need them most.
Dr. Ngeh J. Toyang is the Co-Founder and Chief Executive Officer of Flavocure Biotech, Inc., a clinical-stage biotechnology company pioneering precision therapeutics at the intersection of oncology and neurology. With over 15 years of distinguished research experience in natural products science and pharmacognosy, Dr. Toyang has built his career at some of the world’s leading research institutions including the National Center for Natural Products Research at the University of Mississippi School of Pharmacy, the Natural Products Research Laboratory at Leiden University in The Netherlands, and the Institute of Human Virology at the University of Maryland School of Medicine.
Dr. Toyang earned his PhD specializing in Pharmacognosy from Leiden University, where he developed a deep expertise in the discovery and translational development of bioactive natural compounds. This scientific foundation has guided his work at Flavocure, where he leads a program focused on converting nature-derived molecules into next-generation therapeutics for cancer and neurodegenerative disease.
A prolific inventor and scientist, Dr. Toyang is the co-author of numerous peer-reviewed publications and holds seven patents protecting the proprietary compounds and platforms he has developed, including the foundational intellectual property covering Caflanone (FBL-03G), Flavocure’s lead oncology and CNS candidate. His leadership has been instrumental in advancing Flavocure’s pipeline to the clinical stage, securing two FDA Orphan Drug Designations and FDA clearance of an Investigational New Drug Application for a Phase I clinical trial in pancreatic cancer, a milestone that positions Flavocure at the forefront of a new era in immunomodulation-directed cancer therapy.
David Afzali is the Founder and Chief Executive Officer of Innocatalyze Life Sciences, where he works directly with senior biopharmaceutical leadership to identify and introduce strategically relevant innovation platforms supporting enterprise priorities across commercialization, patient access, and digital enablement. Over a career spanning more than three decades in the global life sciences sector, he has held senior leadership roles across both pharmaceutical companies and leading global consulting organizations. Earlier in his career, David worked within the pharmaceutical industry at organizations including E. Merck (Germany), Sartorius Biotech, Cal Biotech, Endogen, and Oncogene Sciences. He later held senior leadership positions at EY, Capgemini, PA Consulting, IBM Global Business Services, advising many of the world’s leading pharmaceutical companies on growth strategy, commercialization infrastructure, and digital transformation. Throughout his career, he has worked extensively with senior leadership across major biopharma organizations including Johnson & Johnson, Pfizer, Eli Lilly, Regeneron, Merck, AbbVie, and others. He is widely recognized for his deep industry relationships and his ability to bridge emerging innovation with the strategic priorities of large pharmaceutical enterprises.
Dr. Kirby is a board-certified neurologist and nationally recognized expert in Alzheimer’s disease and other neurodegenerative disorders. He specializes in developing drugs for the central nervous system and serves as a consultant to the pharmaceutical industry to advance urgently needed therapeutics for CNS diseases. He has served as a medical officer for several pharmaceutical companies and as a global lead medical monitor on multiple international development programs. He has served on multiple advisory boards for pharmaceutical companies, helping guide the development of compounds targeting neurologic diseases.
He began his professional career in a busy neurology practice before founding several companies, including Pivotal Research Centers, which grew to become one of the nation’s largest freestanding private clinical research organizations. He later sold the company to a publicly traded firm. Dr. Kirby has extensive drug development experience, having served as principal investigator on nearly 400 clinical trials, consulted with numerous pharmaceutical companies, and contributed to the FDA approval of more than 70 new drugs. He has had a role in nearly every drug approved for Alzheimer’s disease.
He has applied his intense curiosity about the world and his scientific experience to crafting science-based thrillers. He is the author of the Amazon bestselling Shadow of Eden, a medical-political thriller that reached number one in both Mystery and Medical Thrillers. His forthcoming trilogy is The Genesis Agenda.
Anthony Deasey is a Chartered Accountant with over 35 years of experience as Chief Financial Officer in both public and private companies. For the last 16 years he has served as CEO, COO and CFO in privately and publicly held medical and biotech companies where he has led financing and raised an excess of $100M with 2 successful exits.
Sewaa Strategies, a strategic advisor to Flavocure, is an innovative biopharma advisory firm. We specialize in creating exponential patient and shareholder value via bridging capital efficient clinical development and complementary business alliances. Sewaa Strategies has successfully developed product portfolios in oncology, autoimmune inflammatory diseases, neurosciences and rare diseases. We offer end to end expertise in business development, business strategy and operational scale up for pre series A to publicly traded biotech companies. Saurabh Sewak, CEO of Sewaa Strategies is a biotech veteran, and has held senior positions at Biogen, TESARO (now GSK), Ispen and currently Foghorn Therapeutics. At Biogen he was the global head of Commercial Assessment and Disease Strategy and built the Commercial Operations capability. At TESARO he led the development of PARPi and PD-1 inhibitors in multiple oncology indications. At Ipsen Saurabh was the Head of the Medical Science Liaison organization for neuroscience and rare diseases. He currently serves as the VP of corporate development at Foghorn Therapeutics. Saurabh is also a Board Vice Chair for the Leukemia and Lymphoma Society New England Region. He is a pharmacist by primary training and received his MS and PhD degrees in Health Care Administration from the University of Mississippi.
Dr. Woolf graduated from the University of Washington (Seattle, Washington) with a BS in Pharmacy; University of California (San Francisco) Ph.D. Pharmaceutical Chemistry and was a Postdoctoral Fellow in Organic Chemistry at John’s Hopkins University School of Medicine. For several years Dr. Woolf has served as a Pharmacokinetics and Drug discovery specialist/consultant for some of the leading pharmaceutical companies such as Pfizer, Inc. Park- Davis/Warner Lambert Co, and Elan Pharmaceuticals. Dr. Woolf is credited for playing a role in the discovery and development Lipitor®. Dr. Woolf has also served for many years as a consultant on drug regulatory affairs, pharmaceutical investment due diligence, and patent issues. Dr. Woolf is also a registered Patent Agent with the USPTO. He is the Author / Co-author of 45, peer-reviewed articles and contributed to the “Handbook of Drug Metabolism”. He was also Associate Editor for the “Journal of Pharmacology and Experimental Therapeutics”. Dr. Woolf is the holder of several honors and awards in his professional field.
Subscribe to Receive News from Flavocure Biotech
